Japanese hemophilia patients monitored on alhemo in new safety study

NCT ID NCT06285071

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks the safety and effectiveness of the drug Alhemo (concizumab) in 23 people with hemophilia A or B in Japan. Participants receive the drug as part of their normal care, and researchers will monitor side effects for about 2 years. The goal is to see how well Alhemo works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Concizumab (Alhemo)
What this could lead to: If successful, this study will confirm that Alhemo is safe and effective for routine use in people with hemophilia A or B in Japan.
What could go wrong: This is an observational study with only 23 participants, so results may not apply to everyone. It is not designed to prove new benefits, only to monitor real-world safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A HAEMOPHILIA B

Contacts and locations

Locations

Hospital of the University of Occupational And Environmental Health Japan_Pediatrics

Kitakyusyu-shi, Fukuoka, 807 8555, Japan
Kagoshima City Hospital_Pediatrics

Kagoshima, 890-8760, Japan
Kyushu university hospital_Pediatrics

Fukuoka, 812-8582, Japan
Mutsu general hospital_Pediatrics

Aomori, 035-8601, Japan
Nanbu Medical Center & Children's Medical Center_Hematology and Oncology

Okinawa, 901-1193, Japan
Novo Nordisk Investigational Site

Toshima City, Tokyo, Japan
Ogikubo Hospital_Blood Coagulation

Tokyo, 167-0035, Japan
Sapporo Tokushukai Hospital_Pediatrics

Hokkaido, 004-0041, Japan
St. Marianna University School of Medicine Hospital_Pediatrics

Kanagawa, 216-8511, Japan
Tokyo Medical University Hospital

Tokyo, 160-0023, Japan
University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology

Okinawa, 901-2725, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.